A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Public ClinicalTrials.gov record NCT05450692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
Study identification
- NCT ID
- NCT05450692
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 594 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2022
- Primary completion
- Oct 5, 2025
- Completion
- Dec 30, 2027
- Last update posted
- Jul 12, 2026
2022 – 2027
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | 36607 | — |
| Research Site | Chandler | Arizona | 85224 | — |
| Research Site | Los Alamitos | California | 90720 | — |
| Research Site | Los Angeles | California | 90017 | — |
| Research Site | Whittier | California | 90603 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | Athens | Georgia | 30607 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Fort Wayne | Indiana | 46804 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Rockville | Maryland | 20852 | — |
| Research Site | Hattiesburg | Mississippi | 39401 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Omaha | Nebraska | 68114 | — |
| Research Site | Reno | Nevada | 89511 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Canton | Ohio | 44718 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Allentown | Pennsylvania | 18103 | — |
| Research Site | York | Pennsylvania | 17403 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Huntsville | Texas | 77340 | — |
| Research Site | Kingwood | Texas | 77339 | — |
| Research Site | Appleton | Wisconsin | 54911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 164 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05450692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 12, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05450692 live on ClinicalTrials.gov.